XM does not provide services to residents of the United States of America.

Tesla to recall over 27,000 Cybertruck vehicles over rear-view image delay



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 2-Tesla recalls more than 27,000 Cybertrucks to fix rear-view camera delay</title></head><body>

Adds background throughout

Oct 3 (Reuters) -Tesla TSLA.O said on Thursday it would recall more than 27,000 Cybertrucks due to delayed rear-view camera images that could impair driver visibility and increase crash risks, adding that a software update would resolve the issue.

The recall affects most Cybertrucks in the U.S. and is the biggest one for the electric truck. Tesla had issued a recall in April to fix a loose accelerator pedal pad and another in June over issues with windshield wipers and exterior trim.

The electric-vehicle maker started deliveries of the Cybertruck in November 2023, after a two-year delay due to production problems and battery-supply constraints. Tesla has not disclosed Cybertruck production or delivery numbers so far.

Tesla CEO Elon Musk launched the Blade Runner-inspired truck to refresh the company's aging lineup amid slowing EV demand.

Issues with the model are closely watched by investors due to the resources Tesla has invested in its development.

The automaker said on Thursday that the Cybertruck's system in the affected vehicles might not complete a shutdown process before it is commanded to boot up, resulting in a delay in displaying the rear-view image.

The image may not appear within two seconds of placing the vehicle in reverse, and the display may appear blank for up to six to eight seconds when the vehicle is shifted into reverse, Tesla said in a report with the U.S. National Highway Traffic Safety Administration.

The company said it identified the issue early last month, and all Cybertrucks currently in production have received the software fix.





Reporting by Deborah Sophia and Gnaneshwar Rajan in Bengaluru; Editing by Abinaya Vijayaraghavan and Mrigank Dhaniwala

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.